All articles tagged: Abnormal weight loss (R63.4)
![]()
HealthDay
01 July at 05.50 PM
American Diabetes Association, June 21-24The annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in diabetes. The conference highlighted the latest advances in di |
![]()
HealthDay
28 June at 03.03 PM
Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep ApneaMetabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity, according to a study published online June 21 in the Journal of the American College of Cardiology.Ali Aminian, |
![]()
HealthDay
26 June at 03.26 PM
ADA: Semaglutide Similarly Effective in Men, Women With Obesity-Linked Heart FailureFor patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide reduces body weight to a greater extent in women but yields similar improvements in heart failure-related symptoms in men and women, according to a study published online June 23 in the Journal of the American College of Cardiology to coinc |
![]()
HealthDay
25 June at 03.02 PM
Home-Administered Treatment Shows Promise for Binge EatingAt-home, self-administered transcranial direct current stimulation (tDCS) and attention bias modification training (ABMT) is feasible, acceptable, and shows promising efficacy for treatment of binge eating, according to a study published online June 6 in BJPsych Open.Michaela Flynn, Ph.D., from King's College London, and colleague |
![]()
HealthDay
19 June at 03.43 PM
Benefits of Roux-en-Y Gastric Bypass Sustained in the Long TermRoux-en-Y gastric bypass (RYGB) is successful in achieving long-term sustained weight loss and diabetes remission, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.John Nguyen-Lee, M.D., from the Geisinger Medical Center in Danville, Pennsylva |
![]()
HealthDay
18 June at 03.46 PM
Multimodal Antiobesity Medications Yield Superior Preoperative Weight LossCombining antiobesity medications enhances preoperative weight loss in individuals with high body mass index (BMI) preparing for metabolic surgery, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.Michael Kachmar, D.O., from the Pennington Biome |
![]()
Evalytics
13 May at 08.50 PM
1 in 8 adults in the US has taken Ozempic or another GLP-1 drug, KFF survey findsThe article discusses a survey showing the rise in popularity of Ozempic, a GLP-1 drug, for type 2 diabetes. It highlights the drug's effectiveness and patient satisfaction, leading to increased prescriptions. However, concerns remain about its cost and accessibility for some patients. |
![]()
Evalytics
19 March at 06.15 AM
Popular weight loss drugs remain out of reach for many who need themDr. Laure DeMattia, a bariatric medicine specialist, highlights the frustration faced by her patients as they struggle to access these medications despite exhausting other weight loss methods. Many patients, particularly those with Medicare and Medicaid, encounter difficulties in obtaining prescriptions for these drugs due to lack of coverage. |
![]()
Evalytics
11 March at 01.08 AM
Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients"Wegovy," an obesity drug, is approved for reducing heart attack and stroke risk. It's a higher-dose version of a diabetes medicine that aids weight loss. The drug's approval signals a new option for tackling obesity-related health risks. |
![]()
Evalytics
14 February at 06.30 PM
Toby Keith’s Death Raises Questions About Stomach Cancer Symptoms, TreatmentToby Keith, a beloved figure in the country music scene, has recently passed away, leaving fans and the music industry in mourning. However, his death has also brought attention to an important health issue: stomach cancer. In this article, we’ll delve into the details of stomach cancer, Toby Keith’s battle with the disease, and what can be learned from his experience. |
![]()
HealthDay
26 January at 10.12 PM
Cancer Risk Increased With Recent Weight LossIndividuals with recent weight loss have a significantly increased risk for cancer during the subsequent 12 months, according to a study published online in the Jan. 23/30 issue of the Journal of the American Medical Association.Qiao-Li Wang, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues examined the rates of subseq |
![]()
HealthDay
23 January at 09.30 PM
Type 2 Diabetes Remission Likely With Weight Loss After DiagnosisRemission of type 2 diabetes is feasible and is associated with weight loss in the year after diabetes diagnosis, according to a study published online Jan. 23 in PLOS Medicine.Hongjiang Wu, from The Chinese University of Hong Kong, and colleagues examined the association of weight change at one year after diabetes diagnosis with long- |
![]()
Evalytics
22 January at 03.05 PM
Dr. Sanjay Gupta: What weight tells us about our healthThe CNN article examines changing views on body weight, discussing obesity's classification as a disease and the rise of effective weight loss medications. It addresses the societal and medical implications, including weight-related stigma and the limitations of BMI, while exploring new perspectives on obesity and health. |
![]()
HealthDay
16 January at 04.30 PM
Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent EffectsUse of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a study published online Oct. 24 in Diabetes.Mona Mashayekhi, M.D., Ph.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined whet |
![]()
HealthDay
12 January at 11.55 PM
FDA Finds No Evidence Linking Wegovy, Ozempic to Suicidal BehaviorsIn a preliminary review, the U.S. Food and Drug Administration says it has found no evidence drugs like Wegovy and Ozempic cause suicidal thoughts or actions.Still, the agency noted officials cannot rule out that "a small risk may exist," and it will continue to look into similar reports involving these glucagon-like peptide-1 receptor agonists. |
![]()
HealthDay
05 January at 10.33 PM
One-Third of Patients Persist on Antiobesity Medications at Six MonthsLater-stage persistence with antiobesity medication (AOM) varies based on the drug and six-month weight loss, according to a study published online Dec. 6 in Obesity.Hamlet Gasoyan, Ph.D., M.P.H., from the Cleveland Clinic, and colleagues examined the percentage of patients with an initial AOM fill who were persistent with AOM at th |
![]()
HealthDay
27 December at 01.22 PM
Cases of Lead Poisoning Linked to Fruit Puree Pouches Reaches 251At least 251 cases of lead poisoning linked to tainted fruit puree pouches have now been reported in 34 states, U.S. health officials said.That's up from 205 cases reported in the last weekly tally, the U.S. Centers for Disease Control and Prevention noted in its <a href="https://www.cdc.gov/nceh/lead/news/lead-poisoning-outbreak-linked- |
![]()
HealthDay
15 December at 05.00 PM
Low-Fat, Vegan Diet Intervention May Reduce Hot FlashesA low-fat vegan diet that includes soy may result in gut microbiome changes that are associated with a decrease in postmenopausal hot flashes, according to a study published in the December issue of Complementary Therapies in Medicine.Hana Kahleova, M.D., Ph.D., from the Physicians Committee for Responsible Medicine in Washington, |
![]()
HealthDay
13 December at 10.08 PM
New Poll Finds Older Americans Believe Medicare Should Cover Weight-Loss DrugsAccording to the latest University of Michigan National Poll on Healthy Aging, about three in four older Americans (76 percent) believe Medicare should cover the cost of weight-loss medications like Ozempic, Wegovy, or Zepbound.More than four out of five older adults (83 percent) think insurance companies should pay for drugs that help people |
![]()
HealthDay
07 December at 04.41 PM
Slow-to-Moderate Weight Loss Linked to Lower Mortality in Knee, Hip OAFor individuals with overweight or obesity and knee or hip osteoarthritis (OA), a slow-to-moderate, but not a fast, rate of weight loss is associated with a reduced risk for all-cause mortality, according to a study published online Dec. 6 in Arthritis & Rheumatology.Jie Wei, Ph.D., from Xiangya Hospital in Changsha, China, and col |
![]()
HealthDay
06 December at 10.55 PM
Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now AvailableEli Lilly has announced that its newly approved weight-loss medication, Zepbound, is now available for patients to take."Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound," Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity, U.S., said in a company news rel |
![]()
Evalytics
05 December at 06.09 PM
Lilly's Mounjaro (tirzepatide) led to more and faster weight loss compared to Novo Nordisk's semaglutide-based drugsIn a study comparing Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, Mounjaro users lost significantly more weight. Over a year, 42.3% of Mounjaro users shed at least 15% body weight, compared to 19.3% with Ozempic. The study, yet to be peer-reviewed, involved over 18,000 patients and showed Mounjaro's superior weight loss effectiveness, with similar side effects to Ozempic. |
![]()
HealthDay
09 November at 04.08 PM
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med MounjaroA second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The weight-loss drug Zepbound contains the same active ingredient, tirzepatide, as the diabetes drug Mounjaro.Zepbound works by activating hormone receptors in the body to reduce appetite |
![]()
HealthDay
08 November at 11.57 PM
FDA Investigating Hospitalizations Linked to Counterfeit OzempicThe U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of semaglutide.At least one of these reports includes mention of a counterfeit version of the Novo Nordisk medication Ozempic, CBS News reported. Ozempic and Wegovy, another semaglutide medication ma |
![]()
HealthDay
08 November at 04.32 PM
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle InterventionTirzepatide provides substantial additional reduction in body weight in participants who already achieved ≥5.0 percent weight reduction with an intensive lifestyle intervention, according to a study published online Oct. 15 in Nature Medicine to coincide with the annual meeting of The Obesity Society (ObesityWeek), held from Oct. 1 |
![]()
HealthDay
07 November at 11.40 PM
American College of Gastroenterology, Oct. 20-25The annual meeting of the American College of Gastroenterology was held from Oct. 20 to 25 in Vancouver, British Columbia, Canada, and attracted participants from around the world, including gastroenterology and digestive disease specialists and other health care professionals. The conference featured presentations focusing on clinical updates in gastr |
![]()
HealthDay
07 November at 04.47 PM
Presenting Weight Loss Treatment as Positive Opportunity Is BeneficialFor patients with obesity seeing a general practitioner, presenting weight loss treatment as a positive opportunity is associated with increased uptake of treatment and more weight loss, according to a study published online Nov. 7 in the Annals of Internal Medicine.Charlotte Albury, D.Phil., from the University of Oxford in the United |
![]()
HealthDay
02 November at 03.38 PM
Time-Restricted Eating Effective for Weight Loss, Lowering HbA1cA time-restricted eating (TRE) intervention without calorie counting is effective for weight loss and lowering hemoglobin A1c (HbA1c) levels among adults with obesity and type 2 diabetes, according to a study published online Oct. 27 in JAMA Network Open.Vasiliki Pavlou, R.D., from the University of Illinois Chicago, and colleagues exa |
![]()
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
![]()
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
![]()
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
![]()
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |
Medpage Today
13 June at 06.56 PM
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60% of melanoma patients who do not benefit or develop resistance to the drugs... |
Medpage Today
08 June at 04.00 PM
Here Are the Top Supreme Court Health Cases to WatchBy early July, the Supreme Court will release its most controversial rulings for the 2023-2024 term. The Court's 6-3 conservative supermajority has already overturned Roe v. Wade, sharply limited affirmative action, expanded... |